Latest Period
Q1 2026
Security Snapshot
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) Institutional Ownership
CUSIP: 88338N206
13F Institutional Holders and Ownership History from Q4 2021 to Q1 2026
Institutions Reporting
47
Shares (Excl. Options)
3,930,452
Price
$2.02
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- TXMD on Nasdaq
- Shares outstanding
- 11,676,558
- Price per share
- $2.07
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 3,930,452
- Total reported value
- $7,939,211
- % of total 13F portfolios
- 0%
- Share change
- +520,174
- Value change
- +$1,050,571
- Number of holders
- 47
- Price from insider filings
- $2.07
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 88338N206.
- 47 institutions reported positions in Q1 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 41 to 47 between Q4 2025 and Q1 2026.
- Reported value moved from $5,517,397 to $7,939,211.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 47 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 88338N206?
CUSIP 88338N206 identifies TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 88338N206:
Significant Owners of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Clearline Capital LP | 5.5% | $705,096 | 635,222 | Clearline Capital LP | 31 Dec 2024 | |||
| Baselake Partners, LP | 5.2% | $1,384,373 | 607,181 | Baselake Partners, LP | 30 Mar 2026 |
As of 31 Mar 2026, 47 institutional investors reported holding 3,930,452 shares of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD). This represents 34% of the company’s total 11,676,558 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Rubric Capital Management LP | 10% | 1,192,191 | 0% | 0.03% | $2,408,226 |
| Clearline Capital LP | 5.4% | 635,222 | 0% | 0.1% | $1,283,148 |
| Squadron Capital Management LLC | 3.6% | 420,421 | 0.34% | $849,250 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 3% | 353,697 | 0% | 0% | $714,468 |
| Tejara Capital Ltd | 3% | 345,852 | -1.4% | 0.23% | $698,621 |
| ADAR1 Capital Management, LLC | 1.8% | 209,210 | 0% | 0.03% | $422,604 |
| RENAISSANCE TECHNOLOGIES LLC | 1.3% | 146,200 | +52% | 0% | $295,324 |
| MORGAN STANLEY | 1.1% | 129,217 | 0% | 0% | $261,018 |
| BlackRock, Inc. | 0.99% | 115,145 | -0.85% | 0% | $232,593 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.94% | 109,817 | +3.5% | 0% | $221,884 |
| CITADEL ADVISORS LLC | 0.59% | 68,314 | +142% | 0% | $137,994 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 63,831 | 0% | 0% | $128,939 |
| STATE STREET CORP | 0.26% | 30,100 | 0% | 0% | $60,802 |
| XTX Topco Ltd | 0.24% | 27,487 | 0% | $55,524 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.18% | 21,220 | -40% | 0% | $42,864 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.15% | 17,000 | 0% | 0% | $34,340 |
| NORTHERN TRUST CORP | 0.14% | 16,093 | -2.2% | 0% | $32,508 |
| DIMENSIONAL FUND ADVISORS LP | 0.09% | 10,706 | 0% | $21,626 | |
| Cygnus Capital Advisors, LLC | 0.08% | 9,069 | 0.01% | $18,000 | |
| Vanguard Global Advisers, LLC | 0.04% | 4,937 | 0% | 0% | $9,973 |
| Tower Research Capital LLC (TRC) | 0.01% | 1,509 | -39% | 0% | $3,048 |
| NATIONAL BANK OF CANADA /FI/ | 0.01% | 610 | 0% | 0% | $1,226 |
| Smartleaf Asset Management LLC | 0.01% | 601 | 0% | 0% | $1,196 |
| UBS Group AG | 0% | 331 | -70% | 0% | $669 |
| JPMORGAN CHASE & CO | 0% | 293 | 0% | 0% | $583 |
Institutional Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,930,452 | $7,939,211 | +$1,050,571 | $2.02 | 47 |
| 2025 Q4 | 3,384,889 | $5,517,397 | +$146,413 | $1.63 | 41 |
| 2025 Q3 | 3,303,788 | $3,542,705 | +$51,253 | $1.08 | 43 |
| 2025 Q2 | 3,255,627 | $3,776,528 | -$96,760 | $1.16 | 39 |
| 2025 Q1 | 3,343,589 | $3,092,849 | -$161,728 | $0.92 | 39 |
| 2024 Q4 | 3,528,745 | $3,034,778 | +$127,744 | $0.86 | 38 |
| 2024 Q3 | 3,379,026 | $5,609,223 | -$32,659 | $1.66 | 34 |
| 2024 Q2 | 3,408,566 | $5,487,879 | -$167 | $1.61 | 34 |
| 2024 Q1 | 3,377,053 | $7,732,812 | +$286,534 | $2.29 | 43 |
| 2023 Q4 | 3,251,877 | $7,316,577 | -$358,133 | $2.25 | 36 |
| 2023 Q3 | 2,987,555 | $9,324,433 | +$112,168 | $3.02 | 36 |
| 2023 Q2 | 3,031,054 | $12,488,021 | -$296,992 | $4.12 | 40 |
| 2023 Q1 | 3,115,140 | $11,682,289 | -$1,635,363 | $3.75 | 38 |
| 2022 Q4 | 3,475,915 | $19,431,091 | +$6,039,029 | $5.59 | 43 |
| 2022 Q3 | 2,070,807 | $13,750,198 | -$489,469 | $6.64 | 29 |
| 2022 Q2 | 1,993,507 | $19,835,726 | +$19,831,622 | $9.95 | 36 |
| 2022 Q1 | 10,800 | $4,104 | +$304 | $0.38 | 2 |
| 2021 Q4 | 10,000 | $3,555 | $0.36 | 1 |